| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002579 | American Journal of Ophthalmology | 2012 | 13 Pages |
Abstract
Primary orbital DLBCL has a more favorable prognosis than systemic DLBCL and may arise from a preexistent hematolymphomatous neoplasm (4 out of 20 cases). In our series, orbital DLBCL had a 57% likelihood of being restricted to the ocular adnexa. Clinical staging was more helpful in predicting outcome than any single immunohistopathologic feature or combination of biomarkers. Orbital radiation of 30 gray in conjunction with systemic chemotherapy with rituximab can achieve disease-specific survival approaching 100% in purely localized cases.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Rebecca C. Stacy, Frederick A. Jakobiec, Martina C. Herwig, Lynn Schoenfield, Arun Singh, Hans E. Grossniklaus,